
Originalarbeiten:

1. Mahnken AH, Bruners P, Stanzel S, Koos R, Mühlenbruch G, Günther RW, **Reinartz P**. Functional imaging in the assessment of myocardial infarction: MR imaging vs. MDCT vs. SPECT. *Eur J Radiol* 2009; 71: 480-5.
2. Gagel B, Piroth M, Pinkawa M, **Reinartz P**, Zimny M, Kaiser HJ, Stanzel S, Asadpour B, Demirel C, Hamacher K, Coenen HH, Scholbach T, Maneschi P, DiMartino E, Eble MJ. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? *BMC Cancer* 2007; 7: 113.
3. Gagel B, Piroth M, Pinkawa M, **Reinartz P**, Krohn T, Kaiser HJ, Stanzel S, Breuer C, Asadpour B, Schmachtenberg A, Eble MJ. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study. *BMC Cancer* 2007; 7:112.
4. Nowak B, Weber C, Schober A, Zeiffer U, Liehn EA, von Hundelshausen P, **Reinartz P**, Schaefer WM, Buell U. 111Indium-oxine labelling affects cellular integrity of hematopoietic progenitor cells. *Eur J Nucl Med Mol Imaging* 2007; 34: 715-721.
5. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen H, Westhofen M, Eble M, Buell U, **Reinartz P**. FDG - a marker of tumour hypoxia? A comparison with [18F]-fluoromisonidazole and pO₂-polarography in metastatic head and neck cancer. *Eur J Nucl Med Mol Imaging* 2006; 33: 1426-1431.

6. Gagel B, Piroth M, Pinkawa M, **Reinartz P**, Zimny M, Fishedik K, Stanzel S, Breuer C, Skobel E, Asadpour B, Schmachtenberg A, Buell U, Eble MJ. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with Gemcitabine/Vinorelbine in locally advanced non-small cell lung cancer. A phase I study. *Strahlenther Onkol* 2006; 182: 263-269.
7. **Reinartz P**, Kaiser HJ, Wildberger JE, Gordji C, Nowak B, Buell U. SPECT imaging in the diagnosis of pulmonary embolism: automated detection of match and mismatch defects by means of image processing techniques. *J Nucl Med* 2006; 47: 968-973.
8. Gagel B, **Reinartz P**, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ. ¹⁸F-fluoromisonidazole and ¹⁸F-fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. *BMC Cancer* 2006; 6: 51.
9. Mumme T, **Reinartz P**, Alfer J, Müller-Rath R, Buell U, Wirtz DC. Diagnostic values of positron emission tomography versus triple-phase bone scan in hip arthroplasty loosening. *Arch Orthop Trauma Surg* 2005; 125: 322-329.
10. **Reinartz P**, Mumme T, Hermanns B, Cremerius U, Wirtz DC, Schaefer WM, Niethard F-U, Buell U. Radionuclide imaging of the painful hip arthroplasty: positron emission tomography versus triple-phase bone scan. *J Bone Joint Surg [Br]* 2005; 87: 465-470.
11. Buell U, Wieres FJ, Schneider W, **Reinartz P**. ¹⁸FDG-PET in 733 consecutive patients with or without side-by-side CT evaluation: Analysis of 921 lesions. *Nuklearmedizin* 2004; 43: 210-216.

12. Schaefer WM, Lipke CSA, Kühl HP, Koch KC, Kaiser HJ, **Reinartz P**, Nowak B, Buell U. Prone versus supine patient positioning during gated ^{99m}Tc -sestamibi SPECT: Effect on left ventricular volumes, ejection fraction, and heart rate. J Nucl Med 2004; 2016-2020.
13. Gagel B, **Reinartz P**, DiMartino E, Zimny M, Pinkawa M, Maneschi P, Stanzel S, Hamacher K, Coenen HH, Westhofen M, Büll U, Eble MJ. pO₂ polarography versus positron emission tomography ([^{18}F] fluoromisonidazole, [^{18}F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004; 180: 616-622.
14. **Reinartz P**, Wieres FJ, Schneider W, Schur A, Buell U. Side-by-side reading of PET and CT scans in oncology: Which patients might profit from integrated PET/CT? Eur J Nucl Med Mol Imaging 2004; 31: 1456-1461.
15. **Reinartz P**, Wildberger JE, Schaefer W, Nowak B, Mahnken AH, Buell U. Tomographic imaging in the diagnosis of pulmonary embolism: a comparison between V/Q lung scintigraphy in SPECT technique and multislice spiral CT. J Nucl Med 2004; 45: 1501-1508.
16. Nowak B, Stellbrink C, Schaefer WM, Sinha AM, Breithardt OA, Kaiser HJ, **Reinartz P**, Hanrath P, Buell U. Comparison of regional myocardial blood flow and perfusion in dilated cardiomyopathie and left bundle branch block: role of wall thickening. J Nucl Med 2004; 45: 414-418.
17. Schaefer WM, Lipke CSA, Nowak B, Kaiser HJ, **Reinartz P**, Buecker A, Krombach GA, Buell U, Kuehl HP. Validation of QGS and 4D-MSPECT for quantification of left ventricular volumes and ejection fraction from gated ^{18}F -FDG PET: comparison with cardiac MRI. J Nucl Med 2004; 45: 74-79.

18. Lipke CSA, Kuehl HP, Nowak B, Kaiser HJ, **Reinartz P**, Koch KC, Buell U, Schaefer WM. Validation of 4D-MSPECT and QGS for quantification of left ventricular volumes and ejection fraction from gated ^{99m}Tc-MIBI SPET: comparison with cardiac magnetic resonance imaging. *Eur J Nucl Med Mol Imaging* 2004; 31: 482-490.
19. Nowak B, Stellbrink C, Sinha AM, Kaiser HJ, **Reinartz P**, Koos R, Markus K, Hanrath P, Buell U, Schaefer WM. Effects of cardiac resynchronization therapy on myocardial blood flow measured by oxygen-15 water positron emission tomography in idiopathic dilated cardiomyopathy and left bundle branch block. *Am J Cardiol* 2004; 93: 496-499.
20. **Reinartz P**, Zimny M, Schaefer W, Mueller B, Buell U, Sabri O. Radioiodine therapy in patients with hyperthyroid disorder: standard versus dosimetric activity application. *Nucl Med Commun* 2003; 24: 1247-1253.
21. Geier A, Gartung C, Dietrich CG, Wasmuth HE, **Reinartz P**, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: effect of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. *World J Gastroenterol* 2003; 9: 2681-2685.
22. Mumme T, **Reinartz P**, Cremerius U, Hermanns B, Müller-Rath R, Neuss M, Büll U, Wirtz DC. Die [F-18]-Fluorodeoxyglucose (FDG) Positronenemissionstomographie (PET) als Differenzialdiagnostikum der Hüftendoprothesenlockerung. *Z Orthop* 2003; 141: 540-546.
23. Cremerius U, Mumme T, **Reinartz P**, Wirtz D, Niethard FU, Büll U. Analyse des 18F-FDG Speichermusters in der PET zur Diagnostik von septischer und aseptischer Lockerung bei Totalendoprothesen des Hüftgelenks. *Nuklearmedizin* 2003; 42: 234-239.

-
24. Zimny M, Hochstenbag M, Lamers R, **Reinartz P**, Cremerius U, ten Velde G, Buell U. Mediastinal staging of lung cancer with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography and a dual-head coincidence gamma camera. *Eur Radiol* 2003; 13: 740-747.
 25. Schaefer WM, Koch KC, Kuhl HP, **Reinartz P**, Kaiser HJ, vom Dahl J, Sabri O, Buell U, Nowak B. Effects of left ventricular volume and ejection on myocardial blood flow measured by oxygen-15 water positron emission tomography in coronary heart disease. *Am J Cardiol* 2003; 91: 469-472.
 26. **Reinartz P**, Sabri O, Zimny M, Nowak B, Cremerius U, Setani K, Büll U. Thyroid volume measurement in patients prior to radioiodine therapy: comparison between three-dimensional magnetic resonance imaging and ultrasonography. *Thyroid* 2002; 8: 713-717.
 27. Cremerius U, Fabry U, Wildberger JE, Simony M, **Reinartz P**, Nowak B, Schäfer W, Büll U, Osieka R. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. *Bone Marrow Transplant* 2002; 30: 103-111.
 28. **Reinartz P**, Schirp U, Zimny M, Sabri O, Nowak B, Cremerius U, Büll U. Optimizing ventilation-perfusion lung scintigraphy: parting with planar imaging. *Nuklearmedizin* 2001; 40: 38-43.
 29. Sabri O, Zimny M, Schreckenberger M, **Reinartz P**, Nowak B, Ostwald E, Schäfer W, Block S, Setani K, Büll U. Charakterisierung von Therapieversagern bei der Radioiodtherapie des Morbus Basedow ohne simultane Thyreostase. *Nuklearmedizin* 2001; 40: 1-6.

-
30. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, **Reinartz P**, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000; 27: 1591-1597.
 31. Nowak B, Zimny M, Schwarz ER, Kaiser HJ, Schaefer W, **Reinartz P**, vom Dahl J, Buell U. Diagnosis of myocardial viability by dual-head coincidence gamma camera fluorine-18 fluorodeoxyglucose positron emission tomography with and without non-uniform attenuation correction. Eur J Nucl Med 2000; 27: 1501-1508.
 32. **Reinartz P**, Schaffeldt J, Sabri O, Zimny M, Nowak B, Ostwald E, Cremerius U, Büll U. Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET. Eur J Nucl Med 2000; 27: 721-726.
 33. Sabri O, Hellwig D, Schreckenberger M, Schneider R, Kaiser H-J, Wagenknecht G, Setani K, **Reinartz P**, Zimny M, Mull M, Ringelstein E-B, Büll U. One-year follow-up of neuropsychology, MRI, rCBF and glucose metabolism (rMRGLu) in cerebral microangiopathy. Nuklearmedizin 2000; 39: 43-49.
 34. Franke J, Rosenzweig S, **Reinartz P**, Höer J, Kasperk R, Schumpelick V. Die Wertigkeit der Positronen-Emissionstomographie (18F-FDG-PET) in der Diagnostik von Rectum-Rezidivcarzinomen. Chirurg 2000; 71: 80-85.
 35. Zimny M, Kaiser H-J, Cremerius U, **Reinartz P**, Schreckenberger M, Sabri O, Büll U. Dual-head gamma camera 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection. Eur J Nucl Med 1999; 26: 818-823.

-
36. Sabri O, Zimny M, Schulz G, Schreckenberger M, **Reinartz P**, Willmes K, U. Büll. Success rate of radioiodine therapy in Graves' Disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84: 1229-1333.
 37. Nowak B, Di Martino E, Jänicke S, Cremerius U, Adam G, Zimny M, **Reinartz P**, Büll U. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999; 38: 312-318.
 38. **Reinartz P**, Zimny M, Cremerius U, Sabri O, Kaiser H-J, Nowak B, Büll U. Quantifizierung von Repositionierungsfehlern bei PET-Studien durch Überlagerung von Emissions- und Transmissionsscan. Nuklearmedizin 1999; 38: 192-198.
 39. Zimny M, Kaiser H-J, Cremerius U, Sabri O, Schreckenberger M, **Reinartz P**, Büll U. F-18-FDG positron imaging in oncological patients: gamma camera coincidence detection versus dedicated PET. Nuklearmedizin 1999; 38: 108-114.
 40. Sabri O, Zimny M, Schreckenberger M, **Reinartz P**, Ostwald E, Büll U. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999; 9: 1181-1888.
 41. Schmitz F-J, Küppers B, **Reinartz P**, Vossel R, Schuppe HC, Bielfeld P, Somville T, Heinz HP. Vergleich verschiedener Methoden zur Detektion von Chlamydia trachomatis in zervikalen und urethralen Abstrichen verschiedener Patientenkollektive. Clin Lab 1996; 42: 1059-1067.

Kasuistiken:

1. Kisielinski K, **Reinartz P**, Mumme T, Büll U. Die FDG-PET stellt Fremdkörperreaktionen gegen Polyethylen-Abriebpartikel in nicht infizierten Knieendoprothesen dar. Nuklearmedizin 2004; 43: N3-N6.
2. Kisielinski K, Cremerius U, **Reinartz P**, Niethard FU. Fluorodeoxyglucose positron emission tomography detection of inflammatory reactions due to polyethylene wear in total hip arthroplasty. J Arthroplasty 2003; 18: 528-532.
3. Setani K, Habermeyer B, **Reinartz P**, Kosinski Ch. Verdacht auf Demenz vom Lewy-Körperchen-Typ: Diagnostik mit ^{18}F -FDG-PET, ^{123}I -IBZM und ^{123}I -FP-CIT. Nuklearmedizin 2003; 42: N56-N59.
4. **Reinartz P**, Wildberger JE, Büll U. Lungenemboliediagnostik bei kongenitalen Fehlbildungen des Herz-Kreislauf-Systems. Nuklearmedizin 2003; 42: N59-N61.
5. Nowak B, Sabri O, Hoff C, **Reinartz P**, Kleinhans E, Zimny M. Unterschiedliche Dynamik von Tc-99m-Tetrofosmin und Tc-99m-MIBI in einem Nebenschilddrüsenadenom. Nuklearmedizin 1999; 38: 160-163.
6. **Reinartz P**, Sabri O, Kinzel S, Zimny M, Bachmann T, Küpper W, Büll U. Die Radioiodtherapie in der Veterinärmedizin: Behandlung der Schilddrüsenüberfunktion bei einer Katze. Nuklearmedizin 1999; 38: 31-34.

Buchbeiträge:

1. **Reinartz P.** Pulmonary Function - Methods in Nuclear Medicine. In: Encyclopedic Reference of Imaging. Baert AL. Berlin, Heidelberg, New York: Springer Verlag 2008; 1546-1549.
2. Büll U, Bares R, **Reinartz P.** Nuklearmedizinische Diagnostik und Therapie. In: Praxis der konservativen Orthopädie. Bischoff HP, Heisel J, Locher H. Stuttgart, New York: Georg Thieme Verlag 2007; im Druck.
3. **Reinartz P,** Sabri O. Lunge. In: Nuklearmedizin. Kuwert T, Haberkorn U, Bartenstein P, Behr TM, Krause TM. Stuttgart, New York: Georg Thieme Verlag 2007; im Druck.

Briefe:

1. De Geeter FW, **Reinartz P,** Büll U. Tomographic imaging in the diagnosis of pulmonary embolism: still, we do not know. J Nucl Med 2005; 46: 2119-2121.
2. **Reinartz P,** Nowak B, Weiss C, Buell U. Thin-collimation multi-detector row spiral CT and planar ventilation-perfusion scintigraphy in the diagnosis of acute pulmonary embolism. Radiology 2004; 232: 621.

Übersichtsarbeiten:

1. **Reinartz P.** FDG-PET in patients with painful hip and knee arthroplasty: technical breakthrough or just more of the same. Q J Nucl Med Mol Imaging 2009; 53:41-50.
2. **Reinartz P,** Büll U. Pulmonary embolism from a nuclear medicine perspective. Controversies and Consensus in Imaging and Intervention. 2005; 3: 9-12.
3. **Reinartz P,** Büll U. Relevanz und Indikationen der Skelettszintigraphie - eine Standortbestimmung. Der Nuklearmediziner 2002; 25: 225-229.

Editorials - Kommentare:

1. **Reinartz P.** To PIOPED, or not to PIOPED. J Nucl Med 2008; 49: 1739-40.
2. Büll U, **Reinartz P.** Quantifizierung in der Skelettszintigraphie mit Tc-99m-Phosphonaten: Determinanten und Bezugspunkte. Nuklearmedizin 2000; 39: N69-N71.